Azacitidine for Treating Acute Myeloid Leukaemia with More Than 30 % Bone Marrow Blasts: An Evidence Review Group Perspective of a National Institute for Health and Care Excellence Single Technology Appraisal

Tikhonova, IA; Hoyle, MW; Snowsill, TM; Cooper, C; Varley-Campbell, JL; Rudin, CE; Mujica Mota, RE; (2017) Azacitidine for Treating Acute Myeloid Leukaemia with More Than 30 % Bone Marrow Blasts: An Evidence Review Group Perspective of a National Institute for Health and Care Excellence Single Technology Appraisal. PharmacoEconomics , 35 (3) pp. 363-373. 10.1007/s40273-016-0453-5 . Green open access

https://ift.tt/2OOaAZJ